Patents by Inventor Wuyi Kong

Wuyi Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NPRCPS, PFDNCS AND USES THEREOF
    Publication number: 20150079045
    Abstract: Identification of a group of novel particle termed “non-platelet RNA-containing particles (NPRCP)” provides novel compositions, downstream products and therapeutic tools. In addition a group of mixed NPRCPs were identified that contain RNAs and proteins. NPRCPs do not have a nucleus and their membrane is not the typical eukaryotic cell membrane. Methods for isolation and enrichment are also provided.
    Type: Application
    Filed: February 12, 2013
    Publication date: March 19, 2015
    Inventor: Wuyi Kong
  • Regenerative dot cells
    Patent number: 8241898
    Abstract: Methods and compositions are provided for the isolation, culture and use of highly regenerative somatic mammalian cells. The cells are very small, and have an undefined nuclear structure. The cells may be isolated from fetal or adult tissues, and are found in tissue including, without limitation, fetal dermal tissue, blood, and bone marrow. The cells are characterized as expressing one or more markers selected from E-cadherin, integrin ?1, CXCR4, CD90 and CD34, and may be selected on the basis of such expression patterns.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: August 14, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Wuyi Kong, Shaowei Li, Peter Lorenz
  • Regenerative Dot cells
    Publication number: 20090155226
    Abstract: Methods and compositions are provided for the isolation, culture and use of highly regenerative somatic mammalian cells. The cells are very small, and have an undefined nuclear structure. The cells may be isolated from fetal or adult tissues, and are found in tissue including, without limitation, fetal dermal tissue, blood, and bone marrow. The cells are characterized as expressing one or more markers selected from E-cadherin, integrin ?1, CXCR4, CD90 and CD34, and may be selected on the basis of such expression patterns.
    Type: Application
    Filed: December 10, 2008
    Publication date: June 18, 2009
    Inventors: Wuyi Kong, Shaowei Li, Peter Lorenz